Assessing the prevalence and severity of cisplatin-induced nephrotoxicity in a minority- low socioeconomic population in the Bronx, New York

Abstract

Studies evaluating Cisplatin-induced nephrotoxicity in minorities are limited. We conducted a retrospective review of adult patients receiving cisplatin from 2019 to 2023 at an inner-city hospital. Renal indices were obtained at baseline and after cycles 1, 2, and 3 of Cisplatin. A total of 93 patients were included, 46% were male. Median age was 57 years. About 40% were Black, 13% White, and 42% Hispanic. About 54% were uninsured. About 16% of the patients developed AKI after cycle 1 of cisplatin, 5% after cycle 2%, and 17% after cycle 3. There was no statistically significant correlation between race, sex, BMI and development of cisplatin-induced AKI. Repeated measures ANOVA test indicated a statistically significant and cumulative rise in creatinine level following cisplatin therapy [Wilks’ Lambda = 0.003, F(1,26)=13.7, η² = 0.44]. Our study in a minority, low socioeconomic population highlights the progressive kidney injury following each cycle of cisplatin therapy. Further studies targeting this specific population are warranted to develop tailored interventions.

Keywords:

• Cisplatin
• nephrotoxicity
• minority
• acute kidney injury (AKI)
• health disparity

Authors’ contributions

MBH contributed to the conception and design of the study, acquisition and analysis of data, drafting the manuscript and figures. PG and JS contributed to acquisition and analysis of data and drafting the manuscript. CV and AS contributed to acquisition and analysis of data and revision of manuscript. AA contributed to conception and design of the study, revision of manuscript and study supervision

Disclosure statement

The authors report there are no competing interests to declare.

Data availability statement

The data that support the findings of this study are available from the corresponding author, MBH, upon reasonable request

Additional information

Funding

None.